TARS Tarsus Pharmaceuticals
- 37.990
- -0.380-0.99%
- 37.990
- 0.0000.00%
Tarsus Pharmaceuticals News
Tarsus Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Tarsus Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Tarsus Pharmaceuticals (TARS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $57.00 to $61.00.
HC Wainwright & Co. : Tarsus Pharmaceuticals (TARS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $57.00 to $61.00.
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $61
HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $57 to $61.
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INK
Analysts Are Betting On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) With A Big Upgrade This Week
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased
Tarsus Pharmaceuticals Is Maintained at Overweight by Barclays
Tarsus Pharmaceuticals Is Maintained at Overweight by Barclays
Barclays: Maintaining the Tarsus Pharmaceuticals (TARS.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $50.00 to $60.00.
Barclays: Maintaining the Tarsus Pharmaceuticals (TARS.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $50.00 to $60.00.
Barclays Maintains Overweight on Tarsus Pharmaceuticals, Raises Price Target to $60
Barclays analyst Balaji Prasad maintains Tarsus Pharmaceuticals with a Overweight and raises the price target from $50 to $60.
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Oppenheimer: The Tarsus Pharmaceuticals (TARS.US) rating was maintained, and the target price was adjusted from better than the market to the superior market rating, and the target price was adjusted from $59.00 to $61.00.
Oppenheimer: The Tarsus Pharmaceuticals (TARS.US) rating was maintained, and the target price was adjusted from better than the market to the superior market rating, and the target price was adjusted from $59.00 to $61.00.
Tarsus Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 70.36% Oppenheimer $59 → $61 Maintains Outperform 03/06/2024 22.88% Jefferies $30 → $44 Maintai
Earnings Call Summary | Tarsus Pharmaceuticals(TARS.US) Q1 2024 Earnings Conference
The following is a summary of the Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript:Financial Performance:Tarsus reported $27.6 million in total revenue, made up of $24.7 million in
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating
Tarsus Pharmaceuticals (TARS) has an average rating of Buy and price targets ranging from $30 to $67, according to analysts polled by Capital IQ. Price: 35.83, Change: -1.52, Percent Change: -4.07
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator,
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
Tarsus Pharmaceuticals | 10-Q: Quarterly report
Tarsus Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Tarsus Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Analysis
Price Target
No Data
